{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:17:48Z","timestamp":1793971068638,"version":"4.8.0"},"reference-count":67,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2020,2,29]]},"DOI":"10.5582\/irdr.2020.01011","type":"journal-article","created":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T22:03:52Z","timestamp":1581804232000},"page":"1-9","source":"Crossref","is-referenced-by-count":129,"title":["A basic understanding of mucopolysaccharidosis: Incidence, clinical features, diagnosis, and management"],"prefix":"10.5582","volume":"9","author":[{"given":"Jing","family":"Zhou","sequence":"first","affiliation":[{"name":"Laboratory for Reproductive Immunology, Hospital & Institute of Obstetrics and Gynecology, Shanghai Medical College, Fudan University, Shanghai, China."},{"name":"The Academy of Integrative Medicine of Fudan University, Shanghai, China."},{"name":"Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[{"name":"Laboratory for Reproductive Immunology, Hospital & Institute of Obstetrics and Gynecology, Shanghai Medical College, Fudan University, Shanghai, China."},{"name":"The Academy of Integrative Medicine of Fudan University, Shanghai, China."},{"name":"Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Ting","family":"Leung","sequence":"additional","affiliation":[{"name":"Laboratory for Reproductive Immunology, Hospital & Institute of Obstetrics and Gynecology, Shanghai Medical College, Fudan University, Shanghai, China."},{"name":"The Academy of Integrative Medicine of Fudan University, Shanghai, China."},{"name":"Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[{"name":"Laboratory for Reproductive Immunology, Hospital & Institute of Obstetrics and Gynecology, Shanghai Medical College, Fudan University, Shanghai, China."},{"name":"The Academy of Integrative Medicine of Fudan University, Shanghai, China."},{"name":"Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gaffke L, Pierzynowska K, Podlacha M, Brokowska J, Wegrzyn G. Changes in cellular processes occurring in mucopolysaccharidoses as underestimated pathomechanisms of these diseases. Cell Biol Int. 2019. [Epub ahead of print]","DOI":"10.1002\/cbin.11275"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Quittot N, Sebastiao M, Bourgault S. Modulation of amyloid assembly by glycosaminoglycans: From mechanism to biological significance. Biochem Cell Biol. 2017; 95:329-337.","DOI":"10.1139\/bcb-2016-0236"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Del Longo A, Piozzi E, Schweizer F. Ocular features in mucopolysaccharidosis: diagnosis and treatment. Ital J Pediatr. 2018; 44:125.","DOI":"10.1186\/s13052-018-0559-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Barone R, Pellico A, Pittala A, Gasperini S. Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses. Ital J Pediatr. 2018; 44:121.","DOI":"10.1186\/s13052-018-0561-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Suarez-Guerrero JL, Gomez Higuera PJ, Arias Florez JS, Contreras-Garcia GA. Mucopolysaccharidosis: Clinical features, diagnosis and management. Rev Chil Pediatr. 2016; 87:295-304.","DOI":"10.1016\/j.rchipe.2015.10.004"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sawamoto K, Stapleton M, Almeciga-Diaz CJ, Espejo-Mojica AJ, Losada JC, Suarez DA, Tomatsu S. Therapeutic options for mucopolysaccharidoses: Current and emerging treatments. Drugs. 2019; 79:1103-1134.","DOI":"10.1007\/s40265-019-01147-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hunter C. A Rare Disease in Two Brothers. Proc R Soc Med. 1917; 10:104-116.","DOI":"10.1177\/003591571701001833"},{"key":"8","unstructured":"8. Grupo de Trabajo Enfermedades poco f, Sociedad Argentina de Pediatria Subcomisiones CyGdT. Consensus on mucopolysaccharidosis type I diagnosis and treatment. Arch Argent Pediatr. 2008; 106:361-368."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ, Chao MC, Chiu PC, Lin SJ, Tsai LP, Hwu WL, Lin JL. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A. 2009; 149A:960-964.","DOI":"10.1002\/ajmg.a.32781"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Chen X, Qiu W, Ye J, Han L, Gu X, Zhang H. Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China. J Hum Genet. 2016; 61:345-349.","DOI":"10.1038\/jhg.2015.155"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Cho SY, Sohn YB, Jin DK. An overview of Korean patients with mucopolysaccharidosis and collaboration through the Asia Pacific MPS Network. Intractable Rare Dis Res. 2014; 3:79-86.","DOI":"10.5582\/irdr.2014.01013"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, Mason RW, Giugliani R, Suzuki Y, Orii KE, Orii T, Tomatsu S. Epidemiology of mucopolysaccharidoses. Mol Genet Metab. 2017; 121:227-240.","DOI":"10.1016\/j.ymgme.2017.05.016"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Malm G, Lund AM, Mansson JE, Heiberg A. Mucopolysaccharidoses in the Scandinavian countries: Incidence and prevalence. Acta Paediatr. 2008; 97:1577-1581.","DOI":"10.1111\/j.1651-2227.2008.00965.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP. The frequency of lysosomal storage diseases in the Netherlands. Hum Genet. 1999; 105:151-156.","DOI":"10.1007\/s004399900075"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Krabbi K, Joost K, Zordania R, Talvik I, Rein R, Huijmans JG, Verheijen FV, Ounap K. The live-birth prevalence of mucopolysaccharidoses in Estonia. Genet Test Mol Biomarkers. 2012; 16:846-849.","DOI":"10.1089\/gtmb.2011.0307"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lowry RB, Applegarth DA, Toone JR, MacDonald E, Thunem NY. An update on the frequency of mucopolysaccharide syndromes in British Columbia. Hum Genet. 1990; 85:389-390.","DOI":"10.1007\/BF00206770"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Muenzer J. The mucopolysaccharidoses: A heterogeneous group of disorders with variable pediatric presentations. J Pediatr. 2004; 144:S27-34.","DOI":"10.1016\/j.jpeds.2004.01.052"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Martins AM, Lindstrom K, Kyosen SO, Munoz-Rojas MV, Thibault N, Polgreen LE. Short stature as a presenting symptom of attenuated mucopolysaccharidosis type I: Case report and clinical insights. BMC Endocr Disord. 2018; 18:83.","DOI":"10.1186\/s12902-018-0311-x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Parini R, Deodato F, Di Rocco M, Lanino E, Locatelli F, Messina C, Rovelli A, Scarpa M. Open issues in mucopolysaccharidosis type I-Hurler. Orphanet J Rare Dis. 2017; 12:112.","DOI":"10.1186\/s13023-017-0662-9"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yamanishi R, Nakamura N, Tsunoda K. Recovery of vision following enzyme replacement therapy in a patient with mucopolysaccharidosis type II, Hunter syndrome. Case Rep Ophthalmol. 2019; 10:186-194.","DOI":"10.1159\/000500804"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Guillen-Navarro E, Domingo-Jimenez MR, Alcalde-Martin C, Cancho-Candela R, Couce ML, Galan-Gomez E, Alonso-Luengo O. Clinical manifestations in female carriers of mucopolysaccharidosis type II: A Spanish cross-sectional study. Orphanet J Rare Dis. 2013; 8:92.","DOI":"10.1186\/1750-1172-8-92"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Chinawa J, Adimora G, Obu H, Tagbo B, Ujunwa F, Onubogu I. Clinical presentation of mucopolysaccharidosis type II (Hunter&apos;s syndrome). Ann Med Health Sci Res. 2012; 2:87-90.","DOI":"10.4103\/2141-9248.96946"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, Meldgaard Lund A, Malm G, Van der Ploeg AT, Zeman J. Mucopolysaccharidosis type II (Hunter syndrome): A clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008; 167:267-277.","DOI":"10.1007\/s00431-007-0635-4"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Nijmeijer SCM, van den Born LI, Kievit AJA, Stepien KM, Langendonk J, Marchal JP, Roosing S, Wijburg FA, Wagenmakers M. The attenuated end of the phenotypic spectrum in MPS III: from late-onset stable cognitive impairment to a non-neuronopathic phenotype. Orphanet J Rare Dis. 2019; 14:249.","DOI":"10.1186\/s13023-019-1232-0"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Jakobkiewicz-Banecka J, Gabig-Ciminska M, Kloska A, Malinowska M, Piotrowska E, Banecka-Majkutewicz Z, Banecki B, Wegrzyn A, Wegrzyn G. Glycosaminoglycans and mucopolysaccharidosis type III. Front Biosci (Landmark Ed). 2016; 21:1393-1409.","DOI":"10.2741\/4463"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Wijburg FA, Wegrzyn G, Burton BK, Tylki-Szymanska A.Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit\/hyperactivity disorder or autism spectrum disorder. Acta Paediatr. 2013; 102:462-470.","DOI":"10.1111\/apa.12169"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. van de Kamp JJ, Niermeijer MF, von Figura K, Giesberts MA. Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C). Clin Genet. 1981; 20:152-160.","DOI":"10.1111\/j.1399-0004.1981.tb01821.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Valstar MJ, Marchal JP, Grootenhuis M, Colland V, Wijburg FA. Cognitive development in patients with mucopolysaccharidosis type III (Sanfilippo syndrome). Orphanet J Rare Dis. 2011; 6:43.","DOI":"10.1186\/1750-1172-6-43"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Xie J, Pan J, Guo D, Pan W, Li R, Guo C, Du M, Jiang W, Guo Y. Mutation analysis and pathogenicity identification of Mucopolysaccharidosis type IVA in 8 south China families. Gene. 2019; 686:261-269.","DOI":"10.1016\/j.gene.2018.11.051"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Khan S, Almeciga-Diaz CJ, Sawamoto K, Mackenzie WG, Theroux MC, Pizarro C, Mason RW, Orii T, Tomatsu S. Mucopolysaccharidosis IVA and glycosaminoglycans. Mol Genet Metab. 2017; 120:78-95.","DOI":"10.1016\/j.ymgme.2016.11.007"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Nagao K, Morlet T, Haley E, Padilla J, Nemith J, Mason RW, Tomatsu S. Neurophysiology of hearing in patients with mucopolysaccharidosis type IV. Mol Genet Metab. 2018; 123:472-478.","DOI":"10.1016\/j.ymgme.2018.02.002"},{"key":"32","unstructured":"32. Tomatsu S, Yasuda E, Patel P, <i>et al.<\/i> Morquio A syndrome: Diagnosis and current and future therapies. Pediatr Endocrinol Rev. 2014; 12 Suppl 1:141-151."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Harmatz P, Shediac R. Mucopolysaccharidosis VI: Pathophysiology, diagnosis and treatment. Front Biosci (Landmark Ed). 2017; 22:385-406.","DOI":"10.2741\/4490"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Thumler A, Miebach E, Lampe C, Pitz S, Kamin W, Kampmann C, Link B, Mengel E. Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: A case series. J Inherit Metab Dis. 2012; 35:1071-1079.","DOI":"10.1007\/s10545-012-9474-1"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010; 5:5.","DOI":"10.1186\/1750-1172-5-5"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Hendriksz CJ, Giugliani R, Harmatz P, Lampe C, Martins AM, Pastores GM, Steiner RD, Leao Teles E, Valayannopoulos V, Group CSPS. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis. 2013; 36:373-384.","DOI":"10.1007\/s10545-011-9410-9"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Lin SP, Shih SC, Chuang CK, Lee KS, Chen MR, Niu DM, Chiu PC, Lin SJ, Lin HY. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--Changes with age and treatment. Pediatr Pulmonol. 2014; 49:277-284.","DOI":"10.1002\/ppul.22774"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Lin HY, Chuang CK, Chen MR, Lin SM, Hung CL, Chang CY, Chiu PC, Tsai WH, Niu DM, Tsai FJ, Lin SJ, Hwu WL, Lin JL, Lin SP. Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI. Mol Genet Metab. 2016; 117:431-437.","DOI":"10.1016\/j.ymgme.2016.02.003"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Azevedo AC, Artigalas O, Vedolin L, Komlos M, Pires A, Giugliani R, Schwartz IV. Brain magnetic resonance imaging findings in patients with mucopolysaccharidosis VI.J Inherit Metab Dis. 2013; 36:357-362.","DOI":"10.1007\/s10545-012-9559-x"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Borlot F, Arantes PR, Quaio CR, Franco JF, Lourenco CM, Bertola DR, Kim CA. New insights in mucopolysaccharidosis type VI: Neurological perspective. Brain Dev. 2014; 36:585-592.","DOI":"10.1016\/j.braindev.2013.07.016"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Montano AM, Lock-Hock N, Steiner RD, <i>et al.<\/i> Clinical course of sly syndrome (mucopolysaccharidosis type VII). J Med Genet. 2016; 53:403-418.","DOI":"10.1136\/jmedgenet-2015-103322"},{"key":"42","unstructured":"42. Genetics Home Reference, National Institutes of Health. Mucopolysaccharidosis type VII. <i>https:\/\/ghr.nlm.nih.gov\/condition\/mucopolysaccharidosis-type-vii<\/i># (accessed Feb. 6, 2020)"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Nathanson MA. Hyaluronates in developing skeletal tissues. Clin Orthop Relat Res. 1990;275-289.","DOI":"10.1097\/00003086-199002000-00047"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Toole BP. Hyaluronan in morphogenesis. Semin Cell Dev Biol. 2001; 12:79-87.","DOI":"10.1006\/scdb.2000.0244"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Triggs-Raine B, Salo TJ, Zhang H, Wicklow BA, Natowicz MR. Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX. Proc Natl Acad Sci U S A. 1999; 96:6296-6300.","DOI":"10.1073\/pnas.96.11.6296"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Natowicz MR, Short MP, Wang Y, Dickersin GR, Gebhardt MC, Rosenthal DI, Sims KB, Rosenberg AE. Clinical and biochemical manifestations of hyaluronidase deficiency. N Engl J Med. 1996; 335:1029-1033.","DOI":"10.1056\/NEJM199610033351405"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Imundo L, Leduc CA, Guha S, Brown M, Perino G, Gushulak L, Triggs-Raine B, Chung WK. A complete deficiency of Hyaluronoglucosaminidase 1 (HYAL1) presenting as familial juvenile idiopathic arthritis. J Inherit Metab Dis. 2011; 34:1013-1022.","DOI":"10.1007\/s10545-011-9343-3"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Brusius-Facchin AC, Rojas Malaga D, Leistner-Segal S, Giugliani R. Recent advances in molecular testing to improve early diagnosis in children with mucopolysaccharidoses. Expert Rev Mol Diagn. 2018; 18:855-866.","DOI":"10.1080\/14737159.2018.1523722"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Colmenares-Bonilla D, Colin-Gonzalez C, Gonzalez-Segoviano A, Esquivel Garcia E, Vela-Huerta MM, Lopez-Gomez FG. Diagnosis of mucopolysaccharidosis based on history and clinical features: Evidence from the Bajio Region of Mexico. Cureus. 2018; 10:e3617.","DOI":"10.7759\/cureus.3617"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. No rt hov er H, C owi e RA, W raith JE . Mucopolysaccharidosis type IVA (Morquio syndrome): A clinical review. J Inherit Metab Dis. 1996; 19:357-365.","DOI":"10.1007\/BF01799267"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Peracha H, Sawamoto K, Averill L, <i>et al.<\/i> Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA. Mol Genet Metab. 2018; 125:18-37.","DOI":"10.1016\/j.ymgme.2018.05.004"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Lum SH, Miller WP, Jones S, Poulton K, Ogden W, Lee H, Logan A, Bonney D, Lund TC, Orchard PJ, Wynn RF. Changes in the incidence, patterns and outcomes of graft failure following hematopoietic stem cell transplantation for Hurler syndrome. Bone Marrow Transplant. 2017; 52:846-853.","DOI":"10.1038\/bmt.2017.5"},{"key":"53","unstructured":"53. Warkentin PI, Dixon MS, Jr., Schafer I, Strandjord SE, Coccia PF. Bone marrow transplantation in Hunter syndrome: A preliminary report. Birth Defects Orig Artic Ser. 1986; 22:31-39."},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Chinen Y, Higa T, Tomatsu S, Suzuki Y, Orii T, Hyakuna N. Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA. Mol Genet Metab Rep. 2014; 1:31-41.","DOI":"10.1016\/j.ymgmr.2013.11.002"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Krivit W, Pierpont ME, Ayaz K, Tsai M, Ramsay NK, Kersey JH, Weisdorf S, Sibley R, Snover D, McGovern MM, <i>et al.<\/i> Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation. N Engl J Med. 1984; 311:1606-1611.","DOI":"10.1056\/NEJM198412203112504"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, Izykowski B, Phillips J, Doroshow R, Walot I, Hoft R, Neufeld EF. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001; 344:182-188.","DOI":"10.1056\/NEJM200101183440304"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Muenzer J, Beck M, Eng CM, <i>et al.<\/i> Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011; 13:95-101.","DOI":"10.1097\/GIM.0b013e3181fea459"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Harmatz P, Ketteridge D, Giugliani R, Guffon N, Teles EL, Miranda MC, Yu ZF, Swiedler SJ, Hopwood JJ, Group MVS. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): Results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005; 115:e681-689.","DOI":"10.1542\/peds.2004-1023"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Fox JE, Volpe L, Bullaro J, Kakkis ED, Sly WS. First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient. Mol Genet Metab. 2015; 114:203-208.","DOI":"10.1016\/j.ymgme.2014.10.017"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Hendriksz CJ. Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A syndrome). Expert Rev Clin Pharmacol. 2016; 9:1521-1532.","DOI":"10.1080\/17512433.2017.1260000"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Schweighardt B, Tompkins T, Lau K, Jesaitis L, Qi Y, Musson DG, Farmer P, Haller C, Shaywitz AJ, Yang K, O&apos;Neill CA. Immunogenicity of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome: Results from MOR-004, a phase III trial. Clin Ther. 2015; 37:1012-1021 e1016.","DOI":"10.1016\/j.clinthera.2014.11.005"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Wolf DA, Lenander AW, Nan Z, Belur LR, Whitley CB, Gupta P, Low WC, McIvor RS. Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I. Neurobiol Dis. 2011; 43:123-133.","DOI":"10.1016\/j.nbd.2011.02.015"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Penati R, Fumagalli F, Calbi V, Bernardo ME, Aiuti A. Gene therapy for lysosomal storage disorders: Recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I. J Inherit Metab Dis. 2017; 40:543-554.","DOI":"10.1007\/s10545-017-0052-4"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Braun SE, Pan D, Aronovich EL, Jonsson JJ, McIvor RS, Whitley CB. Preclinical studies of lymphocyte gene therapy for mild Hunter syndrome (mucopolysaccharidosis type II). Hum Gene Ther. 1996; 7:283-290.","DOI":"10.1089\/hum.1996.7.3-283"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Piotrowska E, Jakobkiewicz-Banecka J, Baranska S, Tylki-Szymanska A, Czartoryska B, Wegrzyn A, Wegrzyn G. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet. 2006; 14:846-852.","DOI":"10.1038\/sj.ejhg.5201623"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Delgadillo V, O&apos;Callaghan Mdel M, Artuch R, Montero R, Pineda M. Genistein supplementation in patients affected by Sanfilippo disease. J Inherit Metab Dis. 2011; 34:1039-1044.","DOI":"10.1007\/s10545-011-9342-4"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Dubot P, Sabourdy F, Plat G, Jubert C, Cances C, Broue P, Touati G, Levade T. First report of a patient with MPS type VII, due to novel mutations in GUSB, who underwent enzyme replacement and then hematopoietic stem cell transplantation. Internatl J of Molec Sciences. 2019; 20.","DOI":"10.3390\/ijms20215345"}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/9\/1\/9_2020.01011\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T03:36:01Z","timestamp":1584761761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/9\/1\/9_2020.01011\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,29]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2020.01011","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,29]]}}}